1 ©2022 KARYOPHARM THERAPEUTICS INC. A Commercial-Stage Pharmaceutical Company Pioneering Novel Cancer Therapies March 2022 Forward-looking Statements and Other Important Information This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Karyopharm's guidance on its 2022 net product revenues and 2022 non-GAAP research and development and selling, general and administrative expen ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36167 KARYOPHARM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 26-3931704 (State ...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2021 Earnings Conference Call February 8, 2022 8:30 AM ET Company Participants Richard Paulson - President, Chief Executive Officer Sohanya Cheng - Chief Commercial Officer Jatin Shah - Chief Medical Officer Michael Mason - Chief Financial Officer Sarah Connors - Vice President, Corporate Communications Conference Call Participants Maury Raycroft - Jefferies Peter Lawson - Barclays Mike Ulz - Morgan Stanley Steve - RBC Capital Markets Eric Joseph - JP Morgan J ...

1 ©2022 KARYOPHARM THERAPEUTICS INC. 3) Karyoph A Commercial-Stage Pharmaceutical Company Pioneering Novel Cancer Therapies January 2022 Forward-looking Statements and Other Important Information This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Karyopharm's preliminary financial information for fourth quarter and full year 2021; guidance on its expected cash runway and 202 ...

1 ©2021 KARYOPHARM THERAPEUTICS INC. Virtual Investor Day December 8, 2021 Forward-looking Statements and Other Important Information This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Karyopharm's guidance on its expected cash runway and 2022 revenue and research and development expenses; expectations and plans relating to XPOVIO or any of its drug candidates, if approved, ...

1 ©2021 KARYOPHARM THERAPEUTICS INC. Business Highlights & Third Quarter 2021 Financial Results November 3, 2021 On Today's Call • Welcome Jason Finkelstein, Investor Relations, Argot Partners • Overview Richard Paulson, President and Chief Executive Officer • Commercial Highlights Sohanya Cheng, SVP, Sales and Commercial Operations • Clinical Pipeline Updates Jatin Shah, MD, Chief Medical Officer • Financial Summary and Guidance Michael Mason, Chief Financial Officer • Closing Remarks Richard Paulson, Pres ...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q3 2021 Earnings Conference Call November 3, 2021 8:30 AM ET Company Participants Jason Finkelstein - Argot Partners Richard Paulson - President & Chief Executive Officer Sohanya Cheng - Senior Vice President-Sales & Commercial Operations Jatin Shah - Chief Medical Officer Mike Mason - Chief Financial Officer Stephen Mitchener - Chief Business Officer Sharon Shacham - Chief Scientific Officer Conference Call Participants Maury Raycroft - Jefferies Peter Lawson - Ba ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36167 Karyopharm Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 26-393 ...

1 ©2021 KARYOPHARM THERAPEUTICS INC. A Commercial-Stage Pharmaceutical Company Pioneering Novel Cancer Therapies September 2021 Forward-looking Statements and Other Important Information This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Karyopharm's guidance on its expected cash runway; expectations and plans relating to XPOVIO for the treatment of adult patients with relap ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36167 Karyopharm Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 26-3931704 ...